SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Maintain Significant Stake in Milestone Pharmaceuticals, Holding 9.99% of Common Shares

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a continued beneficial ownership of 9.99% in Milestone Pharmaceuticals Inc., as of December 31, 2024.

Summary

• RTW Investments, LP and Roderick Wong, M.D. collectively beneficially own 5,640,593 Common Shares of Milestone Pharmaceuticals Inc.
• This ownership represents 9.99% of the company's outstanding Common Shares.
• The calculation of the percentage is based on 53,327,908 shares outstanding as of November 12, 2024, and includes the assumed exercise of 3,134,491 warrants held by the Reporting Persons.
• The terms of the warrants prevent their exercise if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.
• The shares are held by RTW Funds, with RTW Master Fund Ltd. and RTW Innovation Master Fund Ltd. each having the right to receive dividends or proceeds from more than 5% of the shares.
• The filing is an Amendment No. 5 to Schedule 13G, indicating an update to a previously disclosed beneficial ownership position.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative performance indicators or forward-looking statements.

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor in a publicly traded pharmaceutical company. It reflects an investment firm's significant, but passive, stake in Milestone Pharmaceuticals Inc., a common occurrence in the biotechnology and pharmaceutical sectors where specialized funds invest in companies with promising drug pipelines.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity. The 9.99% ownership indicates a substantial, but non-controlling, interest.

Key Dates

Keywords

Milestone Pharmaceuticals, RTW Investments, Roderick Wong, Beneficial Ownership, SEC Filing, Schedule 13G, Common Shares, Investment Adviser, Biotechnology, Pharmaceuticals